In the next 60 seconds inside your body, your colon will keep doing its extremely unglamorous job: squeezing yesterday's nachos along, shedding old cells, hosting a microbiome party with questionable guest control, and quietly hoping nobody starts a tiny cellular reboot of Breaking Bad. Most of the time, all is well. But colorectal cancer often begins as a polyp, a little tissue extra that can sit there for years like an uninvited franchise sequel before turning dangerous.
That is why screening exists. Not because anyone woke up thinking, "You know what this week needs? A camera journey through my large intestine." Screening is the boring hero. The Samwise Gamgee of cancer prevention. Not flashy, but absolutely carrying the plot.
A new post hoc analysis of the COLONPREV Trial asks a very practical question: when people actually stick with a screening strategy, how does one-time colonoscopy compare with stool-based FIT testing every two years?
Colonoscopy: The Director's Cut
Colonoscopy is the big production number. You prep, you clear your schedule, a doctor examines the colon with a camera, and if they find suspicious polyps, they can often remove them right then. It is screening and cleanup crew in one episode.
That ability matters. Colorectal cancer usually develops slowly, often from precancerous polyps. Finding and removing those polyps is like deleting the villain's origin story before Netflix greenlights season two.
But colonoscopy has barriers. It requires bowel prep, sedation in many settings, time off, a ride home, endoscopy capacity, and a personal willingness to participate in what is medically elegant but socially hard to brag about at brunch.
FIT: The At-Home Indie Film
FIT, or fecal immunochemical testing, looks for hidden human blood in stool. No bowel prep. No sedation. No camera. You do it at home and mail or return the kit, which gives it the same low-drama appeal as ordering socks online.
Its weakness is that it does not remove polyps. If FIT is positive, you still need a colonoscopy. Also, FIT only works as a strategy if people keep doing it on schedule. This is not a one-and-done superhero cameo. It is more like a long-running sitcom: the magic is in showing up every season.
What COLONPREV Found
The original COLONPREV trial, reported in The Lancet in 2025, compared invitations to one-time colonoscopy versus biennial FIT among average-risk adults aged 50 to 69 in Spain. Participation was higher in the FIT group than in the colonoscopy group, and FIT was noninferior to colonoscopy for colorectal cancer mortality at 10 years in the invitation-based analysis.
The new Gut paper zooms in differently. It analyzed 17,270 people who actually initiated screening and tried to estimate outcomes under sustained strategies: one-time colonoscopy versus continued FIT every two years. The researchers used inverse probability weighting, which is basically a statistical way of saying, "Let's try to account for the fact that real humans do not behave like obedient spreadsheet cells."
The weighted 10-year risks looked very similar:
- Colorectal cancer incidence: 0.80% with FIT versus 0.86% with colonoscopy
- All-cause mortality: 4.02% with FIT versus 4.09% with colonoscopy
- Colorectal cancer mortality: 0.072% with FIT versus 0.042% with colonoscopy
That last number favored colonoscopy, but the estimate was imprecise, meaning the confidence interval left room for uncertainty. Translation: colonoscopy may have an edge for colorectal cancer death, but this analysis cannot slam the gavel like Judge Judy.
The Real Villain: Non-Adherence
The most useful takeaway is not "colonoscopy wins" or "FIT wins." It is that screening strategies live or die in the messy real world.
If a person refuses colonoscopy, colonoscopy protects exactly zero colons. If a person accepts FIT but lets the kit age in a drawer next to expired coupons and mysterious batteries, FIT also loses its superhero cape. The best screening test is not just the one with the prettiest sensitivity curve. It is the one that gets completed, repeated when needed, and followed by colonoscopy after a positive result.
This is where health systems matter. Reminder letters, easy kit returns, navigation after abnormal results, insurance coverage, endoscopy access, and culturally sane communication all affect whether screening works. The science is not only in the test tube. Sometimes it is in the mailbox.
Why This Matters
Colorectal cancer remains common, but it is unusually screenable. That is the plot twist worth keeping. Unlike many cancers that arrive like jump scares, colorectal cancer often gives us a long preview window. We can catch early cancers. We can remove polyps. We can prevent some cancers from happening at all.
This study supports a less macho, more practical view of screening. Colonoscopy is powerful. FIT is scalable and easier to accept. A program that gets more people screened consistently may beat a theoretically superior test that too many people avoid.
So the winner may be less Avengers: Endgame and more Everything Everywhere All at Once: multiple paths, weird logistics, and a surprisingly emotional message about follow-through.
References
-
Castells A, Quintero E, Chen H, et al. Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial. Gut. 2026. DOI: 10.1136/gutjnl-2026-338896. PMID: 42270316
-
Castells A, Quintero E, Bujanda L, et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025;405(10486):1231-1239. DOI: 10.1016/S0140-6736(25)00145-X. PMID: 40158525
-
Robertson DJ, Dominitz JA, Beed A, et al. Baseline features and reasons for nonparticipation in the CONFIRM study. JAMA Network Open. 2023;6(7):e2321730. DOI: 10.1001/jamanetworkopen.2023.21730. PMID: 37432690
-
Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nature Reviews Gastroenterology & Hepatology. 2022;19:521-531. DOI: 10.1038/s41575-022-00612-y. PMCID: PMC9063618
-
Lopes SR, Martins C, Santos IC, Teixeira M, Gamito É, Alves AL. Colorectal cancer screening: a review of current knowledge and progress in research. World Journal of Gastrointestinal Oncology. 2024;16(4):1119-1133. DOI: 10.4251/wjgo.v16.i4.1119. PMCID: PMC11037045
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.